The authors studied the impact and safety of glucagon-like peptide 1 (GLP-1) receptor agonist therapy in hospitalized diabetes mellitus patients with chronic kidney disease. They found that the use of GLP-1 receptor agonist therapy had better outcomes in patients with glomerular filtration rate (GFR) stages 3 to 5 as compared with GFR stages 1 and 2; for both GFR groups, there were minimal adverse events. This study suggests that the off-label use of GLP-1 receptor agonists for hospitalized DM patients with chronic kidney disease may be useful.

No abstract